Kymera Therapeutics股票讨论区

$Kymera Therapeutics(KYMR.US)$ Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment From Sanofi

$Kymera Therapeutics(KYMR.US)$ Director BVF PARTNERS L P/IL purchased 414.11K shares of Common Stocks on Nov 2, 3, 2023 at an average price of $12.8019 for a total value of $5.3 million.
This transaction involves other related parties: BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL and LAMPERT MARK N.

$Kymera Therapeutics(KYMR.US)$ Kymera Therapeutics: KT-413 (IRAKIMiD) Development to Be Discontinued for Strategic Reasons >KYMR
Dow Jones· 6 mins ago

$Kymera Therapeutics(KYMR.US)$ 40Million in milestone payment and not a single trade in PM? hehehe! well ima put a lowball order and see if it fills? But you better believe i got that SL tight! hehehe

$Kymera Therapeutics(KYMR.US)$ Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE

$Kymera Therapeutics(KYMR.US)$ here

Gainers:
In reaction to earnings/guidance:
• $GoodRx(GDRX.US)$ +38.5%,$EDGIO(EGIO.US)$ +13.5%,$Lemonade(LMND.US)$ +10.7%,$Desktop Metal(DM.US)$ +8.5%,$ShockWave Medical(SWAV.US)$ +8.2%,$Pubmatic(PUBM.US)$ +8.1%,$Olaplex(OLPX.US)$ +7%,$Vivid Seats(SEAT.US)$ +6.4%,$Noble(NE.US)$ +6.3%,$艾斯本科技(AZPN.US)$ +5.4%,$艾伦建材(AAON.US)$ +5%,$Hudbay Minerals(HBM.US)$ +5%,$Vivint Smart Home(VVNT.US)$ +4.9%,$Vivint Smart Home(VVNT.US)$ +4...